Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Anti-amyloid beta (Aβ) monoclonal antibody or Cathinone

Use the filters below to narrow your results.

generic:
None (3) · 3-MMC (1) · Butylone (1) · Cathinone (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Hexedrone (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Pentedrone (1)
brand:
None (14) · Aduhelm (1) · Kisunla (1) · Leqembi (1)
classes: (Click arrow to add another value)
mechanism:
None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (14) · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
starting dose:
None (14) · 10 mg/kg IV every 2 weeks (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
None (14) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
None (14) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · Withdrawn 2024 (1)
routes:
None (14) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (2)
onset:
None (14) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · PET Aβ reduction over months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)
duration:
None (14) · Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)
halflife:
None (14) · ~12.1 days (1) · ~25 days (1) · ~5-7 days (1)
bioavailability:
None (14) · 100% (IV) (3)
pregnancy:
None (14) · Discontinued/withdrawn (1) · Limited data (2)
legal:
None (14) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · Withdrawn from US market January 2024 (1)

Showing below up to 17 results in range #1 to #17.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"